Austin biotech Mol­e­c­u­lar Tem­plates lays off more than 100 staffers as pipeline nar­rows

Mol­e­c­u­lar Tem­plates is rid­ding it­self of a Phase I HER2 as­set and fine-tun­ing its pipeline to fo­cus on three pro­grams and a pre­clin­i­cal Bris­tol My­ers Squibb col­lab­o­ra­tion. With the nar­rowed scope on its so-called en­gi­neered tox­in bod­ies, the Austin, TX biotech is lay­ing off about half of its staff.

That’s a lit­tle more than 100 em­ploy­ees, per an SEC fil­ing. Mol­e­c­u­lar’s lay­offs, ap­proved by its board Wednes­day, add to the dozens of pull­backs in the in­dus­try in the first three months of 2023.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN